| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FLUROTECH Aktie jetzt für 0€ handeln | |||||
| 09.01. | FluroTech Ltd.: FluroTech Ltd. Announces Application for Resumption of Trading, AGM Deficiency Update, and CFO Appointment | 724 | Newsfile | Toronto, Ontario--(Newsfile Corp. - January 9, 2026) - FluroTech Ltd. (TSXV: TEST.H) ("FluroTech" or the "Company") is pleased to announce that it has applied to the NEX board of the TSX Venture... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,830 | +3,84 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 83,17 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 29,310 | -0,20 % | Guggenheim raises Rapport Therapeutics price target to $70 on trial data | ||
| PRAXIS PRECISION MEDICINES | 264,61 | +0,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,250 | 0,00 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| DISC MEDICINE | 79,45 | -0,04 % | Disc Medicine prices $450 million stock offering at $75/share | ||
| ARCUTIS BIOTHERAPEUTICS | 32,810 | 0,00 % | Arcutis BioTherapeutics advances 11% to new 52-week high | ||
| SUMMIT THERAPEUTICS | 16,095 | +0,03 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,130 | +0,11 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| MAZE THERAPEUTICS | 32,450 | 0,00 % | Canaccord stuft Maze Therapeutics mit "Buy" ein - Nierentherapien bieten hohes Kurspotenzial | ||
| ABSCI | 9,070 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| VERADERMICS | 127,66 | +0,34 % | Veradermics' hot streak continues with another phase 3 win in hair loss | ||
| RECURSION PHARMACEUTICALS | 3,665 | +0,14 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| EDGEWISE THERAPEUTICS | 39,730 | -0,05 % | William Blair initiates Edgewise Therapeutics stock with outperform rating | ||
| IMMUNOME | 17,920 | 0,00 % | William Blair initiates Immunome stock coverage with outperform rating |